These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20098234)

  • 21. Divalproex sodium therapy in elderly with dementia-related agitation.
    Pratt CE; Davis SM
    Ann Pharmacother; 2002 Oct; 36(10):1625-8. PubMed ID: 12243614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid in dementia: does an optimal dose exist?
    Dolder CR; Nealy KL; McKinsey J
    J Pharm Pract; 2012 Apr; 25(2):142-50. PubMed ID: 22095580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sodium valproate on behavioral disturbances in elderly outpatients with dementia.
    Mizukami K; Hatanaka K; Ishii T; Iwakiri M; Sodeyama N; Tanaka Y; Asada T
    Geriatr Gerontol Int; 2010 Oct; 10(4):324-6. PubMed ID: 20887626
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.
    Olson DA; Ingram W; Mann JR
    J Clin Psychopharmacol; 2002 Oct; 22(5):529-30. PubMed ID: 12352281
    [No Abstract]   [Full Text] [Related]  

  • 25. The efficacy of divalproex sodium in the treatment of agitation associated with major depression.
    Debattista C; Solomon A; Arnow B; Kendrick E; Tilston J; Schatzberg AF
    J Clin Psychopharmacol; 2005 Oct; 25(5):476-9. PubMed ID: 16160625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproic acid treatment of agitation in dementia.
    Herrmann N
    Can J Psychiatry; 1998 Feb; 43(1):69-72. PubMed ID: 9494750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uses of intravenous valproate in geriatric psychiatry.
    Regenold WT; Prasad M
    Am J Geriatr Psychiatry; 2001; 9(3):306-8. PubMed ID: 11481141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances.
    Kunik ME; Puryear L; Orengo CA; Molinari V; Workman RH
    Int J Geriatr Psychiatry; 1998 Jan; 13(1):29-34. PubMed ID: 9489578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease.
    Profenno LA; Jakimovich L; Holt CJ; Porsteinsson A; Tariot PN
    Curr Alzheimer Res; 2005 Dec; 2(5):553-8. PubMed ID: 16375658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial.
    Porsteinsson AP; Tariot PN; Jakimovich LJ; Kowalski N; Holt C; Erb R; Cox C
    Am J Geriatr Psychiatry; 2003; 11(4):434-40. PubMed ID: 12837672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia.
    Meinhold JM; Blake LM; Mini LJ; Welge JA; Schwiers M; Hughes A
    Drugs Aging; 2005; 22(7):615-26. PubMed ID: 16038575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
    Horne RL; Cunanan C
    J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic.
    Narayan M; Nelson JC
    J Clin Psychiatry; 1997 Aug; 58(8):351-4. PubMed ID: 9515973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic management of agitation in Alzheimer's disease.
    Profenno LA; Tariot PN
    Dement Geriatr Cogn Disord; 2004; 17(1-2):65-77. PubMed ID: 14564127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divalproex sodium as a treatment for borderline personality disorder.
    Wilcox JA
    Ann Clin Psychiatry; 1995 Mar; 7(1):33-7. PubMed ID: 8541935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Divalproex sodium in the treatment of aggressive behavior.
    Wilcox J
    Ann Clin Psychiatry; 1994 Mar; 6(1):17-20. PubMed ID: 7951640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of patient preference and side effects in patients switched from divalproex sodium delayed release to divalproex sodium extended release.
    Minirth FB; Neal V
    J Clin Psychopharmacol; 2005 Feb; 25(1):99-101. PubMed ID: 15643111
    [No Abstract]   [Full Text] [Related]  

  • 38. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
    Tariot PN; Schneider LS; Cummings J; Thomas RG; Raman R; Jakimovich LJ; Loy R; Bartocci B; Fleisher A; Ismail MS; Porsteinsson A; Weiner M; Jack CR; Thal L; Aisen PS;
    Arch Gen Psychiatry; 2011 Aug; 68(8):853-61. PubMed ID: 21810649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients.
    Weiner MF; Tractenberg RE; Sano M; Logsdon R; Teri L; Galasko D; Gamst A; Thomas R; Thal LJ
    J Geriatr Psychiatry Neurol; 2002; 15(2):95-8. PubMed ID: 12083600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of schizoaffective disorder with divalproex sodium.
    DelBello MP; Lopez-Larson MP; Getz GE; Strakowski SM
    Schizophr Res; 2000 Nov; 46(1):77-9. PubMed ID: 11099889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.